MHLW Pharmaceuticals and Medical Devices Safety Information (FY2004)

**FY 2004 (No.200-211)**
Japanese version issued on	No.	Table of contents	PDF
March 31, 2005	211	Important Safety Information (1)Raloxifene Hydrochloride (2)Quetiapine Fumarate (3)Blood Glucose Self-monitoring Kit (those using the glucose dehydrogenase method and coenzyme pyroloquinoline quinone) Revision of PRECAUTIONS (No. 164) Trandolapril (and 4 others)	Full text [321 KB]
February 24, 2005	210	Leflunomide-related interstitial pneumon Important Safety Information (1)Epirubicin Hydrochloride (2)Freeze-dried Sulfonated Human Normal Immunoglobulin, pH4 Treated Acidic Human Normal Immunoglobulin, Polyethylene Glycol Treated Human Normal Immunoglobulin, Freeze-dried Polyethylene Glycol Treated Human Normal Immunoglobulin (3)Telithromycin (4)Prednisolone (oral dosage form) (5)Mizoribine Revision of PRECAUTIONS (No. 163) Mefenamic Acid (and 11 others)	Full text [485 KB]
January 27, 2005	209	Important Safety Information (1)Phtharal Revision of PRECAUTIONS (No. 162) Lisinopril (and 8 others)	Full text [117 KB]
December 21, 2004	208	Important Safety Information (1)Interferon Alfa (NAMALWA) (2)Telithromycin Revision of PRECAUTIONS (No. 161) Amitriptyline Hydrochloride (and 13 others)	Full text [339 KB]
November 25, 2004	207	Important Safety Information (1)Paclitaxel (2)Sodium Rabeprazole Revision of PRECAUTIONS (No. 160) Flurbiprofen (oral dosage form) (and 13 others)	Full text [387 KB]
October 28, 2004	206	Safety measures for shock etc. due to injectable antibiotics etc. Reports on Iressa Tablets 250 prospective study (special investigation) Safety measures for blood glucose monitoring kits	Full text [396 KB]
September 30, 2004	205	Reports on adverse reactions associated with influenza vaccines in FY2003 Post-marketing safety measures for ticlopidine hydrochloride products and Cypher Stent Important Safety Information (1)Tacrolimus Hydrate (oral dosage form, injectable dosage form) Revision of PRECAUTIONS (No. 159) Sevoflurane (and 14 others)	Full text [455 KB]
August 26, 2004	204	Important Safety Information (1)Argatroban (2)Mosapride Citrate (3)Salicylamide / Acetaminophen / Anhydrous Caffeine / Promethazine Methylenedisalicylate (4)Concentrated Glycerin / Fructose Revision of PRECAUTIONS (No. 158) Cabergoline (and 12 others)	Full text [363 KB]
July 29, 2004	203	Serious skin disorders caused by pharmaceuticals Effects of electromagnetic waves from antitheft devices, etc. on medical devices Important Safety Information (1)Monoethanolamine Oleate (2)Clarithromycin (3)Tegafur / Gimeracil / Oteracil Potassium (4)Melphalan (injectable dosage form) Revision of PRECAUTIONS (No. 157) Milnacipran Hydrochloride (and 6 others)	Full text [476 KB]
June 24, 2004	202	Safety measures relating to pharmaceuticals with high risks resulting from mix-ups Important Safety Information (1)Infliximab (Genetical recombination) (2)Imatinib Mesilate (3)Oseltamivir Phosphate Revision of PRECAUTIONS (No. 156) Tandospirone Citrate (and 5 others)	Full text [5.3 MB]
May 27, 2004	201	Important Safety Information (1)Clofedanol Hydrochloride (2)Flavoxate Hydrochloride (3)Vinorelbine Ditartrate (4)Phtharal (5)Fluorouracil (injectable dosage form) (6)Doxazosin Mesilate (7)Sodium Risedronate Hydrate Revision of PRECAUTIONS (No. 155) Lornoxicam (and 18 others)	Full text [324 KB]
April 22, 2004	200	Prevention of overdose by use of OptiPen Pro-1 (insulin self-injection device) Crude drugs and drug products with possible adverse reaction when mistakenly imported due to the similarity in names Change of URL in response to the establishment of the Pharmaceuticals and Medical Devices Agency Health hazard caused by natural health foods and non-approved drugs	Full text [270 KB]